Top 10 retinitis pigmentosa treatment 2020 in 2022

Below are the best information and knowledge on the subject retinitis pigmentosa treatment 2020 compiled and compiled by our own team alltopus:

1. Intravitreally injected hRPCs improve vision in retinitis pigmentosa cases

Author: www.aao.org

Date Submitted: 03/23/2020 11:22 PM

Average star voting: 3 ⭐ ( 81323 reviews)

Summary: In study, treatment demonstrates promising biologic activity, safety profile

Match with the search results: Retinitis pigmentosa is a rare inherited eye disease with no cure. Existing treatments for this condition only help a small number of ……. read more

Intravitreally injected hRPCs improve vision in retinitis pigmentosa cases

2. Retinitis Pigmentosa Research Advances

Author: www.ophthalmologytimes.com

Date Submitted: 02/11/2021 03:16 PM

Average star voting: 4 ⭐ ( 43545 reviews)

Summary: Recent developments in research on retinitis pigmintosa.

Match with the search results: Intravitreal injection of human retinal progenitor cells (hRPCs; jCell) is a novel treatment in development for retinitis pigmentosa (RP) ……. read more

Retinitis Pigmentosa Research Advances

3. Encouraging news for treatment targeting retinitis pigmentosa

Author: www.fightingblindness.org

Date Submitted: 11/12/2021 07:28 PM

Average star voting: 3 ⭐ ( 25782 reviews)

Summary: While most people probably wouldn’t put 2020 in their list of favorite years, it’s certainly turning out to be a good one for jCyte. Earlier this year jCyte entered into a partnership with global ophthalmology company Santen Pharmaceuticals worth up to $252 million. Then earlier this week they announced some encouraging results from their Phase…

Match with the search results: The company plans to launch a Phase 3 trial for the treatment in 2021. The treatment involves intravitreal injection of retinal progenitor cells (RPCs), which ……. read more

Encouraging news for treatment targeting retinitis pigmentosa

4. Restoring Vision To The Blind. Regenerative Medicine Offers New Hope For Retinitis Pigmentosa

Author: blog.cirm.ca.gov

Date Submitted: 03/18/2019 11:11 AM

Average star voting: 4 ⭐ ( 50668 reviews)

Summary: Imagine gradually losing your vision over the course of forty years, waking up every morning with a tiny bit more of your peripheral vision grayed out, until you succumb to complete blindness as more and more photoreceptive cells start failing in your eyes.

Match with the search results: While most people probably wouldn’t put 2020 in their list of favorite years, it’s certainly turning out to be a good one for jCyte….. read more

Restoring Vision To The Blind. Regenerative Medicine Offers New Hope For Retinitis Pigmentosa

5. New gene therapy approach may offer a new treatment for retinitis pigmentosa (RP)

Author: www.jnj.com

Date Submitted: 08/02/2019 10:08 PM

Average star voting: 4 ⭐ ( 11284 reviews)

Summary: A new study shows that gene therapy might be a good approach for X-linked RP and that mini-retinas can be used to study other forms of inherited blindness.

Match with the search results: … gene therapy being developed by Johnson & Johnson that could use your own DNA to potentially help treat retinitis pigmentosa….. read more

New gene therapy approach may offer a new treatment for retinitis pigmentosa (RP)

6. Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results – Stem Cell Research & Therapy

Author: www.webmd.com

Date Submitted: 09/08/2020 04:53 PM

Average star voting: 5 ⭐ ( 84681 reviews)

Summary: The aim of the study was to investigate annual structural and functional results, and their correlation with inheritance pattern of retinitis pigmentosa (RP) patients who were treated with Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs). This prospective, sequential, open-label phase-3 clinical study was conducted at Ankara University Faculty of Medicine, Department of Ophthalmology, between April 2019 and May 2020. The study included 34 eyes from 32 retinitis pigmentosa patients of various genotypes who were enrolled in the stem cells clinical trial. The patients were followed for 12 months after the WJ-MSCs transplantation into subtenon space and evaluated with consecutive examinations. Genetic mutations were investigated using a retinitis pigmentosa panel sequencing method consisting of 90 genes. All patients underwent a complete routine ophthalmic examination with best corrected visual acuity, optical coherence tomography angiography, visual field, and full-field electroretinography. Quantitative data obtained from baseline (T0), 6th month (T1), and 12th month (T2) examinations were compared. According to timepoints at T0, T1, and T2: The mean outer retinal thickness was 100.3 μm, 119.1 μm, and 118.0 μm, respectively (p = 0.01; T0 < T1, T2). The mean horizontal ellipsoid zone width were 2.65 mm, 2.70 mm, and 2.69 mm respectively (p = 0.01; T0 < T1, T2). The mean best corrected visual acuity (BCVA) were 70.5 letters, 80.6 letters, and 79.9 letters, respectively (p = 0.01; T0 < T1, T2). The mean fundus perimetry deviation index (FPDI) was 8.0%, 11.4%, and 11.6%, respectively (p = 0.01; T0 < T1, T2). The mean full-field flicker ERG parameters at T0, T1, and T2: amplitudes were 2.4 mV, 5.0 mV, and 4.6 mV, respectively (p = 0.01; T0 < T1, T2). Implicit time were 43.3 ms, 37.9 ms, and 38.6 ms, respectively (p = 0.01; T0 > T1, T2). According to inheritance pattern, BCVA, FPDI, ERG amplitude, and implicit time data improved significantly in autosomal dominant (AD) and in autosomal recessive (AR) RP at 1 year follow-up (pAD = 0.01, pAR = 0.01; pAD = pAR > pX-linked). No ocular or systemic adverse events related to the surgical methods and/or WJ-MSCs were observed during the 1 year follow-up period. Subtenon transplantation of WJ-MSCs was found to be effective and safe in the treatment of RP during the first year, similar to the sixth month’s results. In autosomal dominant and autosomal recessive inheritance of RP, regardless of the genetic mutations, subtenon administration of WJ-MSCs can be considered an effective and safe option without any adverse effect for slowing or stopping the disease progression. ClinicalTrials.gov, NCT04224207 . Registered 8 January 2020

Match with the search results: Treatment · Acetazolamide: In the later stages, the tiny area at the center of your retina can swell. · Vitamin A palmitate: High doses of this ……. read more

Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results - Stem Cell Research & Therapy

7. Latest News and Press Releases | jCyte Inc.

Author: www.forbes.com

Date Submitted: 09/07/2019 06:47 AM

Average star voting: 3 ⭐ ( 59998 reviews)

Summary: Latest press releases, articles and Media contact for jCyte, Inc.

Match with the search results: Regenerative Medicine Offers New Hope For Retinitis Pigmentosa … In the therapy, scientists injected these genes into the retina’s ……. read more

Latest News and Press Releases | jCyte Inc.

8. jCell Therapy | Retinitis Pigmentosa | Degenerative Retinal Disorders | jCyte Inc.

Author: clinicaltrials.gov

Date Submitted: 12/10/2020 01:45 PM

Average star voting: 5 ⭐ ( 29055 reviews)

Summary: jCell is a first-in-class investigational treatment in late-stage clinical development for retinitis pigmentosa (RP), and other inherited retinal and blinding diseases.

Match with the search results: Intervention Model Description: Two eyes of one patient with RP will be divided into two groups. One eye with more serious retinal atrophy will ……. read more

jCell Therapy | Retinitis Pigmentosa | Degenerative Retinal Disorders | jCyte Inc.

9. AAO 2020: Gene therapy for X-linked retinitis pigmentosa achieves significant visual gains at 1 year

Author: www.ucl.ac.uk

Date Submitted: 06/15/2020 08:31 PM

Average star voting: 4 ⭐ ( 80102 reviews)

Summary: Gene therapy for X-linked retinitis pigmentosa is achieving significant visual gains at 1 year mark.

Match with the search results: New gene therapy approach may offer a new treatment for retinitis pigmentosa (RP). 16 June 2020. A new study shows that gene therapy might be a good ……. read more

AAO 2020: Gene therapy for X-linked retinitis pigmentosa achieves significant visual gains at 1 year

10. Repurposing Bone Marrow Stem Cell Therapy for Vision Loss Caused by Retinitis Pigmentosa – Cures Within Reach

Author: stemcellres.biomedcentral.com

Date Submitted: 04/05/2021 05:46 AM

Average star voting: 3 ⭐ ( 77796 reviews)

Summary:

Match with the search results: Retinitis pigmentosa is a rare and very heterogeneous disease [11,12,13,14,15,16,17,18,19,20,21,22]. For this reason, gene therapy has many ……. read more

Repurposing Bone Marrow Stem Cell Therapy for Vision Loss Caused by Retinitis Pigmentosa - Cures Within Reach

Related Posts

Leave a Reply

Your email address will not be published.